6/3
08:43 am
imvt
Immunovant, Inc. (NASDAQ: IMVT) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $50.00 to $46.00. They now have an "outperform" rating on the stock.
Low
Report
Immunovant, Inc. (NASDAQ: IMVT) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $50.00 to $46.00. They now have an "outperform" rating on the stock.
6/2
07:28 am
imvt
Roivant Sciences: Executing On Huge Buyback Program With More To Come [Seeking Alpha]
Low
Report
Roivant Sciences: Executing On Huge Buyback Program With More To Come [Seeking Alpha]
5/30
12:59 pm
imvt
Immunovant (IMVT) Falls as Q4 Earnings Miss, Pipeline in Focus [Yahoo! Finance]
Low
Report
Immunovant (IMVT) Falls as Q4 Earnings Miss, Pipeline in Focus [Yahoo! Finance]
5/30
12:14 pm
imvt
Immunovant, Inc. (NASDAQ: IMVT) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Medium
Report
Immunovant, Inc. (NASDAQ: IMVT) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
5/30
08:06 am
imvt
Immunovant, Inc. (NASDAQ: IMVT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $51.00 price target on the stock.
Medium
Report
Immunovant, Inc. (NASDAQ: IMVT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $51.00 price target on the stock.
5/29
04:24 pm
imvt
Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024 [Yahoo! Finance]
Low
Report
Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024 [Yahoo! Finance]
5/29
04:01 pm
imvt
Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024
High
Report
Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024
5/13
11:40 am
imvt
Wall Street Analysts Think Immunovant (IMVT) Could Surge 68.63%: Read This Before Placing a Bet [Yahoo! Finance]
Low
Report
Wall Street Analysts Think Immunovant (IMVT) Could Surge 68.63%: Read This Before Placing a Bet [Yahoo! Finance]
5/12
09:12 am
imvt
OmniAb, Inc. (NASDAQ:OABI) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
Low
Report
OmniAb, Inc. (NASDAQ:OABI) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
5/9
04:12 pm
imvt
OmniAb Reports First Quarter 2024 Financial Results and Business Highlights [Yahoo! Finance]
Low
Report
OmniAb Reports First Quarter 2024 Financial Results and Business Highlights [Yahoo! Finance]
4/29
10:50 am
imvt
Batoclimab (IMVT-1401) for Graves' Ophthalmopathy Drug Landscape Report 2024: Market Size, Forecast, and Emerging Insights for 7MM 2019-2032 [Yahoo! Finance]
Low
Report
Batoclimab (IMVT-1401) for Graves' Ophthalmopathy Drug Landscape Report 2024: Market Size, Forecast, and Emerging Insights for 7MM 2019-2032 [Yahoo! Finance]
4/24
07:52 am
imvt
Should You Hold Immunovant (IMVT)? [Yahoo! Finance]
Low
Report
Should You Hold Immunovant (IMVT)? [Yahoo! Finance]
4/22
01:55 pm
imvt
Here's Why You Should Add Immunovant (IMVT) to Your Portfolio [Yahoo! Finance]
Low
Report
Here's Why You Should Add Immunovant (IMVT) to Your Portfolio [Yahoo! Finance]
4/17
01:33 pm
imvt
What Makes Immunovant (IMVT) a New Buy Stock [Yahoo! Finance]
Low
Report
What Makes Immunovant (IMVT) a New Buy Stock [Yahoo! Finance]
4/4
02:17 am
imvt
Immunovant: Strategic Edge In The Autoimmune Sector (Rating Upgrade) [Seeking Alpha]
Low
Report
Immunovant: Strategic Edge In The Autoimmune Sector (Rating Upgrade) [Seeking Alpha]
3/28
08:06 am
imvt
Immunovant, Inc. (NASDAQ: IMVT) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $50.00 price target on the stock.
Medium
Report
Immunovant, Inc. (NASDAQ: IMVT) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $50.00 price target on the stock.
3/25
01:01 pm
imvt
Immunovant, Inc. (NASDAQ: IMVT) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $48.00 price target on the stock.
Medium
Report
Immunovant, Inc. (NASDAQ: IMVT) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $48.00 price target on the stock.
3/22
12:00 pm
imvt
Why Argenx's (ARGX) Stock Price Moved Up 11% on Thursday [Yahoo! Finance]
Low
Report
Why Argenx's (ARGX) Stock Price Moved Up 11% on Thursday [Yahoo! Finance]
3/21
07:06 am
imvt
HanAll Biopharma Reports Full-Year 2023 Financial Results and Provides Business Update [Yahoo! Finance]
Low
Report
HanAll Biopharma Reports Full-Year 2023 Financial Results and Provides Business Update [Yahoo! Finance]
3/20
04:16 pm
imvt
OmniAb Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights [Yahoo! Finance]
Medium
Report
OmniAb Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights [Yahoo! Finance]